Flamel's Strategy
By combining the Company's established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners.The Company’s business model is to leverage its proprietary technology platforms through partnership agreements. Flamel applies this strategy to its own drug candidates as well as to the re-formulation of already marketed drugs and the development of new chemical entities with partner companies.
Flamel's Alliances
Flamel Technologies has currently partnerships with the following companies :| Company | Product/Description | Indications | Technology | Status |
|---|---|---|---|---|
| Corning Inc. | SunSensors (photochromic lenses) | Not applicable | PHOTOCHROMIC | Launched |
| GlaxoSmithKline | COREG CR | Cardiovascular diseases | MICROPUMP | Launched |
| Servier Monde | Undisclosed Ace Inhibitor | Undisclosed | MICROPUMP | Undisclosed |
| Wyeth | Undisclosed Marketed Protein | Undisclosed | MEDUSA | Undisclosed |
| Merck Serono | Undisclosed Therapeutic Protein | Undisclosed | MEDUSA | Undisclosed |
Flamel has other undisclosed partnerships.